VintaBio manufactures AAV and lentiviral vectors for entities pursuing clinical development of cell and gene therapies. The contract development manufacturing organization’s launch comes as demand for viral vectors continues to outpace the supply of these crucial components of the therapies.
RALEIGH - Opus Genetics recently announced it would open its third preclinical trial, just a few months after the company formed with a $19 million seed
Ocular gene therapy biotech launches with $19M seed funding biopharma-reporter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharma-reporter.com Daily Mail and Mail on Sunday newspapers.
Opus Genetics, launching from Raleigh-based Retinal Degeneration Fund, raises $19M wraltechwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wraltechwire.com Daily Mail and Mail on Sunday newspapers.